Request Demo
Last update 06 Jun 2026
Universal allogeneic anti-CD19/BCMA CAR T-cells(Changzhou No.2 People's Hospital)
Last update 06 Jun 2026
Overview
Basic Info
Drug Type CAR-T |
Synonyms- |
Target |
Action modulators |
Mechanism BCMA modulators(B-cell maturation protein modulators), CD19 modulators(B-lymphocyte antigen CD19 modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with Universal allogeneic anti-CD19/BCMA CAR T-cells(Changzhou No.2 People's Hospital)NCT06978738
A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
100 Clinical Results associated with Universal allogeneic anti-CD19/BCMA CAR T-cells(Changzhou No.2 People's Hospital)
Login to view more data
100 Translational Medicine associated with Universal allogeneic anti-CD19/BCMA CAR T-cells(Changzhou No.2 People's Hospital)
Login to view more data
100 Patents (Medical) associated with Universal allogeneic anti-CD19/BCMA CAR T-cells(Changzhou No.2 People's Hospital)
Login to view more data
100 Deals associated with Universal allogeneic anti-CD19/BCMA CAR T-cells(Changzhou No.2 People's Hospital)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 1 | China | 01 May 2025 | |
| Autoimmune Haemolytic Anaemias | Phase 1 | China | 01 May 2025 | |
| Immunoglobulin G4-Related Disease | Phase 1 | China | 01 May 2025 | |
| Myasthenia Gravis | Phase 1 | China | 01 May 2025 | |
| Myositis | Phase 1 | China | 01 May 2025 | |
| Scleroderma, Diffuse | Phase 1 | China | 01 May 2025 | |
| Systemic Lupus Erythematosus | Phase 1 | China | 01 May 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free